Treprostinil Diolamine

DRUG2 trials

Sponsors

United Therapeutics, Mardi Gomberg -Maitland MD, MSc

Conditions

Pulmonary Arterial HypertensionPulmonary Hypertension Due to Left Heart Disease

Phase 2

Telemonitoring to Treat Group 2 Pulmonary Hypertension

WithdrawnNCT04882774

Mardi Gomberg -Maitland MD, MScPulmonary Hypertension Due to Left Heart Disease

Start: 2023-04-30End: 2027-04-30Updated: 2023-06-06

Phase 3

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

CompletedNCT01560624

United TherapeuticsPulmonary Arterial Hypertension

Start: 2012-06-26End: 2018-06-24Updated: 2020-02-13

Related Papers

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial

American Journal of Respiratory and Critical Care Medicine2019-11-25141 citations

Long‐term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics

Pulmonary Circulation2019-07-101 citations